X-Linked Retinitis Pigmentosa Pipeline Appears Robust With 5+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight's, "X-linked Retinitis Pigmentosa Pipeline Insight, 2023," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in X-linked Retinitis Pigmentosa pipeline landscape. It covers the X-Linked Retinitis Pigmentosa pipeline drug profiles, including X-Linked Retinitis Pigmentosa clinical trials and nonclinical stage products. It also covers the X-Linked Retinitis Pigmentosa pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

In the X-Linked Retinitis Pigmentosa Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, X-Linked Retinitis Pigmentosa NDA approvals (if any), and product development activities comprising the technology, X-linked Retinitis Pigmentosa collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Key takeaways from the X-Linked Retinitis Pigmentosa Pipeline Report

• X-linked Retinitis Pigmentosa Pipeline report offers a comprehensive analysis of 5+ companies and 5+ therapies.

• The leading X-linked Retinitis Pigmentosa Companies includes Biogen, 4 D Molecular therapeutics, Applied Genetics Technology Corporation, and others.

• Promising X-linked Retinitis Pigmentosa Pipeline Therapies includes AAV2/5-RPGR, docosahexaenoic acid OR corn/soy oil placebo, and others.

• The X-linked Retinitis Pigmentosa companies and academics are working to assess challenges and seek opportunities that could influence X-linked Retinitis Pigmentosa R&D. The X-linked Retinitis Pigmentosa pipeline therapies under development are focused on novel approaches to treat/improve X-linked Retinitis Pigmentosa.

Explore more information on the latest breakthroughs in the X-Linked Retinitis Pigmentosa treatment landscape of the report and X-Linked Retinitis Pigmentosa Pipeline Outlook @ https://www.delveinsight.com/sample-request/x-linked-retinitis-pigmentosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

X-Linked Retinitis Pigmentosa Overview

X-linked Retinitis Pigmentosa is a rare, hereditary progressive genetic disorder associated with the gene mutation in chromosome X of an individual. This disorder is characterized by the progressive degeneration of photoreceptor cells in the retina and gradually leading to peripheral vision loss. Total population affected by X-linked Retinitis Pigmentosa is 1 in 4000 people across the world. Also, as it is a recessive disorder, males are more affected as compared to females, who have two X chromosomes making them carrier for the disorder. Early symptoms for X-linked Retinitis Pigmentosa includes night blindness, and progressive loss of visual field.

X-linked Retinitis Pigmentosa Emerging Drugs Profile

• BIIB 112 (NSR-RPGR): Biogen
Biogen's lead drug candidate, BIIB 112 (NSR-RPGR), is a class of gene therapy molecule which consists of standard AAV8 vector carrying a codon-optimized RPGR gene. The drug is in Phase II/III stage for the treatment of rare X-linked Retinitis Pigmentosa and has been designated orphan drug status. The trial is carried out to evaluate the tolerability as well as the stability of the drug in improving central vision.

• 4D-125: 4 D Molecular Therapeutics
4D Molecular Therapeutics "lead" drug 4D-125 is currently being evaluated for the safety and maximum tolerance dose for the treatment of X-linked Retinitis Pigmentosa. 4D-125 is an AAV gene therapy with an optimized vector designed to deliver a functional RPGR gene copy to the photoreceptors in retina.

Request a sample and discover the recent advances in X-Linked Retinitis Pigmentosa Pipeline Therapies, visit X-Linked Retinitis Pigmentosa Treatment Landscape @ https://www.delveinsight.com/sample-request/x-linked-retinitis-pigmentosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

X-Linked Retinitis Pigmentosa Pipeline Therapeutics Assessment
There are approx. 5+ key companies which are developing the therapies for X-linked Retinitis Pigmentosa. The companies which have their X-linked Retinitis Pigmentosa drug candidates in the mid to advanced stage, Phase II/III include, Biogen and others.

X-Linked Retinitis Pigmentosa Pipeline Segmentation

Phases
• Late-stage products (Phase II/III)
• Mid-stage products (Phase II and Phase I/II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

X-linked Retinitis Pigmentosa Route of Administration
• Subcutaneous
• Intravenous
• Oral
• Intramuscular
• Molecule Type

X-linked Retinitis Pigmentosa Molecule Types
• Small molecules
• Natural metabolites
• Monoclonal antibodies
• Product Type

Get to know more information about the X-linked Retinitis Pigmentosa Emerging Drugs and Companies of the report @ https://www.delveinsight.com/sample-request/x-linked-retinitis-pigmentosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the X-linked Retinitis Pigmentosa Pipeline Report

• Coverage- Global

• X-linked Retinitis Pigmentosa Companies- Biogen, 4 D Molecular therapeutics, Applied Genetics Technology Corporation, and others.

• X-linked Retinitis Pigmentosa Pipeline Therapies- AAV2/5-RPGR, docosahexaenoic acid OR corn/soy oil placebo, and others.

• X-linked Retinitis Pigmentosa Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

To know more facts about the X-linked Retinitis Pigmentosa Pipeline Insights Report, View Here- X-linked Retinitis Pigmentosa Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/x-linked-retinitis-pigmentosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. X-linked Retinitis Pigmentosa: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. X-linked Retinitis Pigmentosa - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. X-linked Retinitis Pigmentosa Collaboration Deals
9. Late Stage Products (Phase II/III)
10. BIIB 112 (NSR-RPGR): Biogen
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase I/II)
13. 4D-125: 4 D Molecular Therapeutics
14. Drug profiles in the detailed report…..
15. Pre-clinical and Discovery Stage Products
16. Drug profiles in the detailed report…..
17. Inactive Products
18. X-linked Retinitis Pigmentosa Key Companies
19. X-linked Retinitis Pigmentosa Key Products
20. X-linked Retinitis Pigmentosa- Unmet Needs
21. X-linked Retinitis Pigmentosa- Market Drivers and Barriers
22. X-linked Retinitis Pigmentosa- Future Perspectives and Conclusion
23. X-linked Retinitis Pigmentosa Analyst Views
24. X-linked Retinitis Pigmentosa Key Companies
25. Appendix
For further information, refer to the detailed X-Linked Retinitis Pigmentosa Pipeline report, visit X-Linked Retinitis Pigmentosa Emerging Drugs & Companies @ https://www.delveinsight.com/sample-request/x-linked-retinitis-pigmentosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Trending Market Research Reports 2032 | DelveInsight

Technical Due Diligence Firms- https://www.delveinsight.com/consulting/due-diligence-services

Vital Sign Monitors Devices Market- https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market

Stem Cell Market- https://www.delveinsight.com/report-store/stem-cell-market

Anastomosis Device Market- https://www.delveinsight.com/report-store/anastomotic-leak-devices-market

Asperger Syndrome Market- https://www.delveinsight.com/report-store/asperger-syndrome-market

B-Cell Maturation Antigen Targeted Therapies Market- https://www.delveinsight.com/report-store/b-cell-maturation-antigen-targeted-therapies-market

UK Healthcare Report- https://www.delveinsight.com/report-store/uk-healthcare-outlook-report

Oncolytic Virus Cancer Therapy Pipeline- https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-pipeline-insight-2021

Shingles Market- https://www.delveinsight.com/report-store/shingles-market

Progressive Supranuclear Palsy Market- https://www.delveinsight.com/report-store/progressive-supranuclear-palsy-market

Tay-Sachs Disease Market- https://www.delveinsight.com/report-store/tay-sachs-disease-market

Shigellosis Market- https://www.delveinsight.com/report-store/shigellosis-market

Gene Therapy In CNS Disorder Market- https://www.delveinsight.com/report-store/gene-therapy-in-cns-disorder-market

Hypertrophic Cardiomyopathy Market- https://www.delveinsight.com/report-store/hypertrophic-cardiomyopathy-market

Varicella Zoster (HHV-3) Infections Market- https://www.delveinsight.com/report-store/varicella-zoster-hhv-3-infections-market

Vasculitis Market- https://www.delveinsight.com/report-store/vasculitis-market

Vascular Imaging Devices Market- https://www.delveinsight.com/report-store/vascular-imaging-market-market

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.